RX-0201-Nano: Nanoliposomal Anti-cancer Akt-1 Inhibitor

RX-0201 nano-liposomal formulation of RX-0301 that is being developed in collaboration with Zhejiang Haichang Biotechnology Co., in China using Haichang's proprietary QTzomeā„¢ technology to treat hepatocellular carcinoma (HCC), the most common form of liver cancer.


We are interested in exploring partnerships for our programs on a global or regional basis. For additional information about our products or to inquire about partnering opportunities, please reach out to us.

Learn More About Partnering